Wellorithm Review

Wellorithm is a current consumer telehealth site covering weight management, longevity, and sexual health. Its terms describe Wellorithm as a facilitator that connects users with licensed healthcare professionals through unnamed professional entities. The terms do not name a legal operator, medical group, or pharmacy.

Florida lists WELLORITHM FIT4ME SYSTEMS LLC as an active Florida LLC filed in April. The site does not disclose or link that entity, and the registry's principal and mailing addresses do not match the site's Miami contact address. This review therefore treats it as a possible related registration, not a verified operator.

The campaign names Ana Lisa Carr, MD, Kelly Tenbrink, MD, and David Mansour, DO, as partner physicians. Current NPPES records show active individual NPIs for doctors with those exact names and credentials. NPPES supports identity and taxonomy checks, not proof that a named physician will treat every patient or that every separate board claim is current.

The public care sequence begins with an online assessment, followed by licensed-provider review, a prescription decision, pharmacy fulfillment when approved, and ongoing support. No patient information was entered during research. The site does not define one review time, consultation format, universal lab rule, or treatment-specific state table.

The normalized section contains only compounded semaglutide injection, compounded tirzepatide injection, and compounded subcutaneous NAD+. Oral GLP-1 routes, branded drug packages, unresolved-route sermorelin, and the four-ingredient tadalafil product remain editorial-only. A brand, formula, route, dose, or billing option does not become a separate therapy.

The current campaign lists compounded semaglutide at $147 and tirzepatide at $249, each advertised as $100 off the first cycle. Current first-party configuration identifies regular one-cycle prices of $247 and $349 and prepaid three-month totals of $645 and $947. The terms say weight-loss membership fees are billed every 28 days.

Because a 28-day cycle is not a calendar month and the three-month options are not clearly comparable standard schedules, the GLP-1 cards do not calculate an average. They display $247 per 28-day cycle and $349 per 28-day cycle, exclude introductory discounts, and remain outside direct rankings.

The NAD+ page says $150 for the first month and then $200 per month for a 500 mg, 2.5 mL vial. It also says the shown price applies to a three-month plan paid upfront or through buy-now-pay-later, while the shared selector reuses $150 for one- and three-month choices. The card uses the explicit $200 recurring amount and remains outside ranking.

Sermorelin is advertised at $150 for the first month and then $200 per month, with a separate three-month configuration of $540 and a regular total of $600. The page calls it an injection and identifies a 5 mL, 10 mg vial but does not state the subcutaneous route required by the reusable AllyRx record. It remains editorial-only.

The tadalafil page describes Daily Rise Tadalafil as a four-ingredient product but does not name all four ingredients. Its visible page has no price. The current configuration says $55 first month and $75 recurring, while its one-month price object says $99 and $149 regular. No price or standalone tadalafil relationship is used.

The campaign says there is no membership or hidden fee, everything is included, and shipping is free. The terms call the program a membership, say it bills every 28 days, and state that product prices exclude shipping and taxes. The selected checkout total and renewal cadence control.

The terms say processed payments are nonrefundable and cancellation by email stops future cycles without refunding the current one. The weight-loss guarantee is narrower than its headline: eligibility depends on new-user status, no weight-loss medication in the prior year, 16 weeks of adherence, a 10% threshold, evidence, review, and approval.

State coverage is unresolved. The campaign says Wellorithm serves 49 states and excludes Louisiana, while the terms say all 50 states plus D.C. Age language also conflicts: the terms say users must be 18 and then allow minors with guardian consent, while the privacy policy says the service is not intended for minors.

Treatment pages advertise free expedited or two-day shipping, supplies for NAD+ and sermorelin, and discreet tadalafil packaging. No dispensing pharmacy, universal order-to-door estimate, temperature-control standard, damage window, or replacement procedure is public. Terms separately say shipping may be excluded from product prices.

The public site contains visible unfinished and copied material, including a `change description to` instruction, NAD+ headings and claims on the sermorelin page, wrong quiz links, unrelated social accounts, an unrelated iframe link, and conflicting Miami and template addresses. These are usability findings, not proof about clinical outcomes.

Most highlighted products are compounded. Compounded drugs are not FDA approved and do not receive FDA premarket review for safety, effectiveness, or quality. Confirm the active ingredient, route, concentration, additives, dose, quantity, pharmacy, storage, and instructions on the prescription and pharmacy label.

The affiliate relationship remains pending. Internal records show $400 as the default approved-sale payout and up to $500 for the highest treatment tier, but payout and EPC do not affect the editorial score. No issued tracking URL or affiliate-compatible promotion is recorded, so the local CTA uses the canonical site and shows no offer.